Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
The overarching aim is to assess the role of microglial activation and norepinephrine
transporter binding in pathogenesis of MS-related fatigue, using novel Positron Emission
Tomography (PET) radiotracers, [F-18]PBR06 and [C-11]MRB.
Specific Aims:
Specific Aim 1: To determine the relationship of cerebral microglial activation, as assessed
by [F-18]PBR06 PET, with MS-related fatigue.
Specific Aim 2: To determine the relationship of norepinephrine transporter (NET) binding, as
assessed by [C-11]MRB PET, with MS-related fatigue.
Specific Aim 3: To determine the relationship of microglial activation and NET binding, with
grey matter pathology (lesion load and brain atrophy) assessed using 7T MRI, and evaluate
their independent contribution in development of MS-related fatigue.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborators:
U.S. Army Medical Research Acquisition Activity United States Department of Defense